IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer

European Respiratory Journal

Volumn 49, Issue 4, 2017, Pages

  Khiroya, Heena ^a   Moore, Jasbir S ^a   Ahmad, Nabeel ^b   Kay, Jamie ^c   Woolnough, Kerry ^d   Langman, Gerald ^d   Ismail, Iyad ^d   Naidu, Babu ^a,d   Tselepis, Chris ^a   Turner, Alice M ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WALSALL HEALTHCARE NHS TRUST   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON REGULATORY PROTEIN 2; IRON; IRP2 PROTEIN, HUMAN;

AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FUNCTION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DMT1 GENE; FEMALE; FTL GENE; GENE; GENE EXPRESSION; GENE SILENCING; HIF1A GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IREB2 GENE; IRON CHELATION; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; SURVIVAL RATE; TFRC GENE; WESTERN BLOTTING; CANCER STAGING; CELL LINE; EPITHELIUM CELL; GENE KNOCKDOWN; GENETICS; LUNG; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL PROLIFERATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IRON; IRON REGULATORY PROTEIN 2; LUNG; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 85034647962     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00711-2016     Document Type: Article

References (46)

1. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172: 523–529.
2. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194–1210.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
4. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307: 2418–2429.
5. Broderick P, Wang Y, Vijayakrishnan J, et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res 2009; 69: 6633–6641.
6. DeMeo D, Mariani T, Bhattacharya S, et al. Integration of genetic and genomic techniques identifies IREB2 as a COPD susceptibility gene. Am J Hum Genet 2009; 85: 493–502.
7. Fehringer G, Liu G, Pintilie M, et al. Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. Cancer Epidemiol Biomarkers Prev 2012; 21: 1097–1104.
8. Khiroya H, Turner AM. The role of iron in pulmonary pathology. Multidiscip Respir Med 2015; 10: 34–40.
9. Maffettone C, Chen G, Drozdov I, et al. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS One 2010; 5: e10163.
10. Brookes MJ, Hughes S, Turner FE, et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 2006; 55: 1449–1460.
11. Boult J, Roberts K, Brookes MJ, et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 2008; 14: 379–387.
12. Masters JR, Stacey GN. Changing medium and passaging cell lines. Nat Protoc 2007; 2: 2276–2284.
13. Cory G. Scratch-wound assay. Methods Mol Biol 2011; 769: 25–30.
14. Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009; 64: 156–161.
15. Riemer J, Hoepken HH, Czerwinska H, et al. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 2004; 331: 370–375.
16. Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol 2013; 83: 179–190.
17. Turner A, McGowan L, Millen A, et al. Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. Eur Respir J 2013; 41: 410–416.
18. Nair A, Klusmann MJ, Jogeesvaran KH, et al. Revisions to the TNM staging of non-small cell lung cancer: rationale, clinicoradiologic implications, and persistent limitations. Radiographics 2011; 31: 215–238.
19. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006; 130: 1026–1030.
20. Chen J, Chloupkova M. Abnormal iron uptake and liver cancer. Cancer Biol Ther 2009; 8: 1699–1708
21. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469–480.
22. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311–320.
23. Brookes MJ, Boult J, Roberts K, et al. A role for iron in Wnt signalling. Oncogene 2008; 27: 966–975.
24. Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994; 56: 379–382.
25. Thelander L, Graslund A, Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun 1983; 110: 859–865.
26. Sanchez M, Galy B, Dandekar T, et al. Iron regulation and the cell cycle: identification of an iron-responsive element in the 3’-untranslated region of human cell division cycle 14A mRNA by a refined microarray-based screening strategy. J Biol Chem 2006; 281: 22865–22874.
27. Li L, Ljungman M, Dixon JE. The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53. J Biol Chem 2000; 275: 2410–2414.
28. Vashisht AA, Zumbrennen KB, Huang X, et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science 2009; 326: 718–721.
29. Pham DH, Powell JA, Gliddon BL, et al. Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1. Oncogene 2014; 33: 5559–5568.
30. Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000; 20: 627–662.
31. Wang W, Deng Z, Hatcher H, et al. IRP2 regulates breast tumor growth. Cancer Res 2014; 74: 497–507.
32. Radulescu S, Brookes MJ, Salgueiro P, et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep 2012; 2: 270–282.
33. Fukushima T, Kawabata H, Nakamura T, et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 2011; 31: 1741–1744.
34. Kovacevic Z, Chikhani S, Lovejoy DB, et al. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol 2011; 80: 598–609.
35. Nurtjahja-Tjendraputra E, Fu D, Phang JM, et al. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 2007; 109: 4045–4054.
36. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007; 6: 1982–1994.
37. Bedford MR, Ford SJ, Horniblow RD, et al. Iron chelation in the treatment of cancer: a new role for deferasirox? J Clin Pharmacol 2013; 53: 885–891.
38. Fujita Y, Takeshita F, Mizutani T, et al. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci Rep 2013; 3: 3325.
39. Sartori S, Nielsen I, Masotti M, et al. Early and late hyperferremia during cisplatin chemotherapy. J Chemother 1991; 3: 45–50.
40. Corhay JL, Weber G, Bury T, et al. Iron content in human alveolar macrophages. Eur Respir J 1992; 5: 804–809.
41. Ghio AJ, Hilborn ED, Stonehuerner JG, et al. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect. Am J Respir Crit Care Med 2008; 178: 1130–1138.
42. Fischer BM, Domowicz DA, Zheng S, et al. Neutrophil elastase increases airway epithelial nonheme iron levels. Clin Transl Sci 2009; 2: 333–339.
43. Cloonan SM, Glass K, Laucho-Contreras ME, et al. Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med 2016; 22: 16–74.
44. Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ 2016; 23: 369–379.
45. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15: 234–245.
46. Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156: 317–331.